MINNEAPOLIS, July 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that new clinical evidence demonstrating the efficacy of its Aquadex^? system will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place September 27-30, 2024, in Atlanta, Georgia.

The study, conducted by Dr. Wayne Old, MD, an advanced heart failure cardiologist at Sentara Health, based out of Sentara Norfolk General Hospital in Norfolk, Va., highlights the benefits of Aquadex ultrafiltration therapy for heart failure patients experiencing fluid overload who have not responded to traditional diuretic treatments. The research underscores Aquadex’s ability to effectively manage fluid levels, providing a critical therapeutic alternative for this challenging patient population.

“We are excited to share our findings at the upcoming HFSA conference,” said Dr. Wayne Old. “Our research demonstrates the efficacy of Aquadex in improving patient outcomes where diuretics have failed. This data supports the integration of ultrafiltration therapy via the Aquadex system into standard practice for managing fluid overload in heart failure patients, providing a new therapy option for patients needing decongestion.”

Nestor Jaramillo, President and CEO of Nuwellis, expressed his gratitude to Dr. Old and his team for their dedicated research efforts. “We extend our deepest appreciation to Dr. Old and his research team for their invaluable work in validating the effectiveness of Aquadex,” said Jaramillo. “Nuwellis is committed to providing robust clinical data to support the use of our therapy. There are many heart failure patients hospitalized due to the symptoms of fluid overload who continue to be treated with diuretics despite their known inefficacy. Aquadex not only offers a more effective solution but also presents significant economic savings to hospitals by reducing the length of hospital stays and associated healthcare costs.”

Sentara Health is also actively participating in REVERSE-HF, a pivotal clinical study on ultrafiltration using Aquadex. REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) is evaluating the clinical outcomes and economic value of Aquadex ultrafiltration therapy in comparison to intravenous (IV) diuretics for the treatment of fluid overload in patients with worsening heart failure.

Dr. Amin Yehya, MD, MS, FACC, FHFSA is the site principal investigator for the REVERSE-HF trial, the medical director of the durable mechanical circulatory support at Sentara Health, and an advanced heart failure and transplant cardiologist. "We are excited to participate in REVERESE-HF and examine Aquadex SmartFlow therapy in our heart failure patients experiencing fluid overload," stated Dr. Yehya. “We are looking forward to confirming the efficacy of ultrafiltration for our patients who do not respond to diuretics. Currently, diuretics are the sole treatment available for the acute relief of heart failure congestion with over 40% of the patients unresponsive to the therapy. Simplified ultrafiltration has demonstrated that it has the potential to change that and offer long-term benefits for heart failure management. REVERSE-HF is set to provide the evidence.”